Follow the money: How biopharma CEOs and workers got paid in 2018

Most drugmaker CEOs received hefty pay raises in 2018, despite a year in which the share prices of many companies declined, according to a BioPharma Dive analysis of financial filings.

BioPharma Dive looked at nearly 200 life sciences companies, ranging from pharmaceutical giants to small biotechs with market values of at least $500 million. The review compiled data on CEO and median employee compensation, stock performance and gender representation.